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Observational study of vaccine efficacy 14 years after trial
of hepatitis B vaccination in Gambian children
Hilton Whittle, Shabbar Jaffar, Michael Wansbrough, Maimuna Mendy, Uga Dumpis,
Andrew Collinson, Andrew Hall
Abstract
Objective To determine the duration of protection
from hepatitis B vaccine given in infancy and early
childhood.
Design Cross sectional serological study of hepatitis B
virus infection in children of various ages 14 years
after the start of a trial of vaccination regimens.
Setting Two villages in the Gambia.
Participants Children and adolescents given hepatitis
B vaccine in infancy or early childhood: 232 were
aged 1›5 years, 225 aged 5›9 years, 220 aged 10›14
years, and 175 aged 15›19 years.
Main outcome measures Vaccine efficacy against
infection and against chronic infection in the different
age groups.
Results Vaccine efficacy against chronic carriage of
hepatitis B virus was 94% (95% confidence interval
89% to 97%), which did not vary significantly between
the age groups. Efficacy against infection was 80%
(76% to 84%). This was significantly lower in the
oldest age group (65%, 56 to 73). Of the uninfected
participants in this age group, 36% had no detectable
hepatitis B virus surface antibody. Time since
vaccination and a low peak antibody response were
the most powerful risk factors for breakthrough
infection (P < 0.001 in each case). Low peak antibody
response was also a risk factor for chronic carriage
(odds ratio 95, 19 to 466).
Conclusions Children vaccinated in infancy are at
increased risk of hepatitis B virus infection in the late
teens. The risk of chronic carriage after sexual
exposure needs further assessment to determine if
booster vaccines are necessary.
Introduction
Chronic infection with hepatitis B virus is a leading
cause of death from cancer in Africa; a quarter of the
60 million carriers die either of primary hepatocellular
carcinoma or cirrhosis of the liver.1 2 However,
although hepatitis B vaccination is the simplest and
most effective intervention to prevent mortality in
adults both globally and in Africa,2 only one country in
west Africa and two in southern Africa have a continu›
ing vaccination programme.
The Gambian programme was started in 1986 as
part of a 40 year trial to test the efficacy of vaccination
against hepatitis B in the prevention of hepatocellular
carcinoma.3 Before this trial epidemiological studies
were undertaken in the two villages of Manduar and
Keneba, where transmission of hepatitis B virus was
found to be largely horizontal, from older to younger
children, and rates of infection and chronic carriage,
which were high, varied markedly between the
villages.4 5 Trials of different routes of administration of
vaccine were started in these villages in 19846 and vac›
cination has been continued thereafter.7 8 Nine years
later vaccine efficacy against either infection or chronic
carriage was 93%.8 Another long term study from
Senegal, which was small due to major losses to follow
up, reported efficacies 9 to 12 years after vaccination of
63% fir infection and 87% for chronic carriage.9
We investigated vaccine efficacy against infection
and protection against chronic carriage after 14 years.
Methods
The demographic and medical background of the vil›
lages of Keneba and Manduar, which in 1998 had
populations of 1474 and 607 respectively, has been
described previously.4 Surveys of hepatitis B virus
infections in these villages took place in 1973, 1980,4
1984,5 1989,7 and 19938 and from November 1998 to
March 1999. At the time of the third survey in Novem›
ber 1984 all children under the age of 5 years who
were seronegative for hepatitis B virus infection were
vaccinated. These children were assigned randomly to
receive plasma derived vaccine against hepatitis B virus
(H›B›Vax, Merck Sharpe & Dohme) according to one
of three vaccination regimens: group 1 was given three
doses of 2 ìg intradermally, group 2 received 2 ìg
intradermally followed by two 20 ìg intramuscular
doses, and group 3 received three doses of 20 ìg intra›
muscularly.5 Subsequent vaccination of newborn
infants has continued with four doses of various
vaccines given intramuscularly: group 4 received 10 ìg
H›B›Vax, group 5 received recombinant vaccines (5 ìg
Recombivax, Merck Sharpe & Dohme, and later 10 ìg
Energix B, SmithKline Beecham), and group 6
received plasma derived vaccine (2.5 ìg Hepaccine,
Cheil Foods and Chemicals).8 There were no side
effects apart from transient tenderness and slight
swelling at the site of injection.
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Concentrations of antibody to hepatitis B virus sur›
face antigen (anti›HBsAg) were measured two months
after vaccination (peak antibody), and this and other
tests for hepatitis B virus core antibody (anti›HBc) and
hepatitis B virus surface antigen (HBsAg) were carried
out at each survey. The laboratory and statistical meth›
ods, the definitions of infection, breakthrough infec›
tion, chronic carriage, and the full details of the vaccine
regimens have been described previously.8 The study
and consent procedures were approved by the
Gambian government and the Medical Research
Council ethics committee.
Results
By the time of the 1998 survey 1041 young people
(833 aged 0›14 years, 208 aged >15 years) had been
vaccinated in the two villages. We excluded from the
study 29 infants who were below 1 year of age and 23
children who had received two or fewer doses of
vaccine, leaving 989 children. Of these 989, 856 gave a
blood sample, 64 refused to take part, 33 had died, and
36 could not be traced; coverage ranged from 94% for
children aged 1›4 years to 81% for those between 15
and 19 years.
Effect of vaccination on pattern of infection
The figure shows that in 1984 at the start of vaccination
Manduar had a much higher prevalence of hepatitis B
virus infection and HBsAg carriage compared with
Keneba. Between 1984 and 1998 vaccination dramati›
cally reduced the prevalence of hepatitis B virus infec›
tion in children from 48% (302/620) to 11% (68/624)
in Keneba and from 80% (246/309) to 15% (34/223)
in Manduar. The corresponding changes in HBsAg
carriage rates were from 13% (83/622) to 1% (6/628)
in Keneba and from 35% (108/309) to 2% (4/227) in
Manduar.
Vaccine efficacy by village and age
Overall, crude vaccine efficacy against HBsAg carriage
was 94% (95% confidence interval 89% to 97%), which
did not vary significantly between villages or by age
group (table 1). Overall crude vaccine efficacy against
infection was 80% (76% to 84%), which did not vary
between villages but differed according to age group,
being significantly lower among those aged >15 years
compared with any of the other younger age categories
(P < 0.001). After we adjusted for age and village, the
overall vaccine efficacy against carriage was 94% (89%
to 97%) and against infection was 82% (78% to 85%).
Duration of response and breakthrough infections
in children immunised in 1984
Table 2 shows the data obtained from groups 1, 2, and
3 at the various surveys. These participants had a
median age in 1998 of 16.2 years (range 14.2›21.7
years) and had been followed up for a median of 13.8
(13.5›14.1) years. In each of the groups, which had sig›
nificantly different peak antibody responses in 1985
(P < 0.0001), antibody decayed in a similar and regular
exponential manner with time. The proportion of
uninfected participants with undetectable antibody
concentrations ( < 10 mIU/ml) differed between the
groups (P=0.001) and increased with time (P < 0.0001).
The proportion of breakthrough infections and the
cumulative proportion of breakthrough infections
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Effect of vaccination against hepatitis B infection on prevalence of hepatitis B virus surface
antigen (HBsAg) and hepatitis B virus core antibody (anti›HBc) in two villages in the Gambia
Table 1 Vaccine efficacy in 1998 against chronic carriage of hepatitis B virus and breakthrough infection overall by village and by
age group
Chronic carriage Breakthrough infection
No infected in vaccine
v control
Vaccine efficacy (%)
(95% CI)
No infected in vaccine
v control
Vaccine efficacy (%)
(95% CI)
Overall 10/855 v 191/931 94 (89 to 97) 102/847 v 564/929 80 (76 to 84)
Keneba 6/628 v 83/622 93 (84 to 97) 68/624 v 302/620 78 (72 to 82)
Manduar 4/227 v 108/309 95 (87 to 98) 34/223 v 246/309 81 (74 to 86)
<5 years (group 6) 3/235 v 68/354 93 (79 to 98) 14/232 v 140/354 85 (74 to 91)
5›9 years (group 5) 0/225 v 66/309 100 10/224 v 309/509 93 (85 to 96)
10›14 years (group 4) 2/220 v 39/191 96 (82 to 99) 33/220 v 156/190 82 (75 to 87)
>15 years (groups 1, 2, 3) 5/175 v 18/77 88 (68 to 95) 53/171 v 68/76 65 (56 to 73)
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(consisting of current infections and past infections
that were no longer detectable) also increased with
time (P < 0.0001 in both cases), but neither of these
proportions differed significantly between the groups.
By 1998, 64 of the 171 (37.4%) vaccinated participants
had been infected, and of the 111 uninfected
participants, 40 (36%) had undetectable concentra›
tions of antibody.
Vaccine efficacy against infection was 49.2% (27.8%
to 64.3%), 36.2% (4.7% to 57.3%), and 92.3% (57.2% to
100%) for groups 1, 2, and 3, respectively (P < 0.01 for
comparison between group 1 or 2 and 3). In 1998 one
of 54 (2%), 4 of 57 (7%), and none of 64 participants in
groups 1, 2, and 3 were chronic carriers of HBsAg. Two
of the chronic carriers were infected within a year of
vaccination; the three others were infected five or more
years later. Vaccine efficacy against chronic carriage
was 91.0% (36.8% to 98.7%), 65.8% (11.3% to 86.8%),
and 100% for groups 1, 2, and 3, respectively.
Breakthrough infections and chronic carriage
according to peak antibody responses
Table 3 shows that the number of breakthrough infec›
tions was related to vaccination group (P=0.01) and to
the peak antibody concentration (P=0.001). Those with
an undetectable (equivalent to < 10 mIU/ml) response
had six times the chance of infection compared with
those with high responses ( > 999 mIU/ml). More
importantly, participants whose peak antibody
response was < 10 mIU/ml were 75 times more likely
to become chronic carriers than those with responses
> 10 mIU/ml (P < 0.0001). Seven out of the 10 chronic
carriers, all of whom had a peak antibody response of
less than 10 mIU/ml, were infected before the age of
5 years.
Logistic regression analyses of breakthrough
infections and chronic carriage
Table 4 shows the independent factors associated with
breakthrough infection. Time since vaccination and
peak antibody concentrations were strongly associated;
sex and village had a significant but lesser effect. Dose
(three or four) was not significant; neither was route of
administration.
The only factor associated with chronic carriage of
hepatitis B virus was a peak response of < 10 mIU/ml
(8/39 (20.5%) versus 2/731 (0.27%) children with a
higher response (odds ratio 95, 95% confidence
interval 19 to 466)).
Discussion
We have shown that despite low antibody concentra›
tions, vaccine efficacy against chronic carriage of hepa›
titis B virus is remarkably well maintained in
adolescence. However, vaccine efficacy against infec›
tion was also well maintained as 37% of teenagers were
infected and 36% of those who were uninfected had
undetectable concentrations of anti›HBs.
Natural boosting and immunity
The role of natural boosting in maintaining immunity
in highly endemic settings is not clear. In our study
antibody concentrations in uninfected older teenagers
stabilised over the previous four years, perhaps as a
result of increased exposure by the sexual route. In a
larger cohort of Gambian people vaccinated in infancy,
we have noted transient rises in antibody concentra›
tions, which may be due to transient infections and
which probably boost both cellular and humoral
immunity.10 11 The role, if any, that sexual exposure
plays in maintaining and boosting immunity remains
to be defined and at present there are insufficient data
to decide if a booster dose would be useful in teenagers
in highly endemic areas where 15% of sexual partners
may be chronic carriers of hepatitis B virus.4 12 In an
area of low endemicity teenagers vaccinated in infancy
may lose immunity because of lack of exposure, and a
booster dose may be necessary at the onset of sexual
maturity. In this setting it may be more sensible to
deliver the primary course of vaccine in adolescence.
Table 2 Concentrations of antibody to hepatitis B surface antigen (anti›HbsAg) and
number infected over time among vaccinated children in groups 1›3
Year of survey
No
tested*
Proportion (%) with
anti›HBsAg <10 mIU/ml
among those uninfected†
Geometric mean
(95% CI) anti›HBsAg
(mIU/ml)‡ among those
uninfected
No
infected
at time
of survey
No ever
infected§
Group 1
1985 53 8/47 (17) 302 (216 to 422) 7 7
1989 48 9/37 (24) 60 (37 to 97) 10 11
1993 47 4/30 (13) 31 (21 to 46) 15 19
1998 52 11/30 (37) 67 (38 to 120) 21 24
Group 2
1985 57 3/50 (6) 579 (421 to 796) 7 7
1989 53 10/42 (24) 65 (45 to 95) 11 11
1993 49 5/37 (14) 32 (24 to 44) 10 16
1998 56 12/34 (35) 60 (30 to 120) 18 23
Group 3
1985 62 0/62 (0) 1045 (758 to 1442) 2 2
1989 61 3/55 (5) 134 (83 to 216) 4 6
1993 59 5/47 (11) 97 (59 to 162) 8 12
1998 63 17/47 (36) 79 (45 to 140) 14 17
*Refers to total number tested for anti›HB core antigen but not necessarily for anti›HBsAg.
†Uninfected at time of survey.
‡Excludes those with anti›HBs <10 mIU/ml.
§Includes current and past infections.
Table 3 Hepatitis B virus infection and chronic carriage in 1998 in relation to peak antibody concentration. Figures are numbers of
breakthrough infections out of total number of children with antibody response
Group and time of vaccination
Peak antibody concentration (mIU/ml)
<10 10›99 100›999 >999 Total
Group 1 (Nov 84›May 85) 9*/10 (90) 5/9 (56) 4/26 (15) 3/6 (50) 21/51 (41)
Group 2 (Nov 84›May 85) 3†/5 (60) 1/3 (33) 11/32 (34) 3*/16 (19) 18/56 (32)
Group 3 (Nov 84›May 85) 0/0 2/2 (100) 4/22 (18) 8/39 (21) 14/63 (22)
Group 4 (Oct 85›Sep 89) 2*/5 (40) 1/8 (13) 10*/37 (27) 11/141 (8) 24/191 (13)
Group 5 (Oct 89›Sep 93) 0/1 0/9 4/34 (12) 5/146 (3) 9/190 (5)
Group 6 (Oct 93›Jul 98) 5†/18 (28) 3/27 (11) 3/73 (4) 3/101 (3) 14/219 (6)
Overall 19/39 (49) 12/58 (21) 36/224 (16) 33/449 (7) 100/770 (13)
*One breakthrough infection resulted in chronic carriage.
†Three breakthrough infections resulted in chronic carriage.
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Risk factors for breakthrough infection
Independent risk factors associated with breakthrough
infection were sex, village, time since vaccination, and
peak antibody response. Boys and young men had a
higher risk, as did people living in Manduar, which
before vaccination had a remarkably high rate of infec›
tion of 71% in young children over a four year period.5
As age and type of vaccine were directly linked in
groups 4, 5, and 6 we were not able to analyse these
effects separately for the whole dataset. However, in
participants in groups 1, 2, and 3, who were simultane›
ously given different doses by different routes, time
since vaccination seemed to be a major determinant.
Breakthrough infections and chronic carriage were
clearly and strongly related to peak antibody
concentrations. Thus half of the children who failed to
produce detectable concentrations of antibody became
infected, most within the first five years after
vaccination, and of those infected nearly half became
chronic carriers. However, as the numbers were small
and as vaccines, dose, and routes of administration var›
ied we were not able to assess formally which of these
factors were the most important determinants of
breakthrough infections resulting in chronic carriage
of hepatitis B virus.
Other long term follow up studies
Few of the follow up studies of infants or young
children vaccinated against hepatitis B virus have
lasted longer than 10 years.9 13–15 The longest was in
China, where 52 of the original 477 children (11%)
were followed for 15 years: half had detectable concen›
trations of anti›HBs, and vaccine efficacy was 86.6% for
chronic carriage and 86.4% for infection.15 This small
study with a large dropout rate formed the basis for a
recent consensus statement that no hepatitis B virus
booster was required for 15 years after primary
vaccination.16 However as the age at first sexual
intercourse may be higher in China than in Africa the
findings may not be generally applicable to other
groups who start sexual activity earlier.17
In conclusion, our long term study of hepatitis B
vaccination in infancy in a country where the infection
is endemic showed that vaccine efficacy against
infection waned with time but efficacy against chronic
infection remained high over 14 years. However, the
numbers involved are relatively small and a larger
study of efficacy during adolescence is necessary before
we conclude that a booster dose is not needed before
the onset of sexual activity.16 In Africa and elsewhere,
the risk of infection and of chronic carriage might be
increased by the presence of other sexually transmitted
infections, as is the case for HIV›1.18
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